Profiles

Gheorghe Doros, PhD

Professor, Biostatistics - Boston University School of Public Health

617-358-2494
doros@bu.edu
Crosstown Center - 331
View Full Profile at BUMC

Biography

Gheorghe Doros is Professor of Biostatistics and director of the Biostatistics Consulting Group. He received his PhD in Statistics from Yale University and joined BUSPH’s Department of Biostatistics in 2006 after spending two years at Eli Lilly, as a member of that company's Drug Discovery and Toxicology department. Dr. Doros’s research on methodological approaches and strategies has been concentrated in the area of clinical trials, more specifically on Bayesian approaches to clinical trials and the area of placebo response in clinical trials. The outcome of his work has been a corner stone in developing a host of collaborations with outstanding faculty, clinicians, and researchers at the Boston University Medical Campus and at other institutions. These productive collaborations have resulted in several federally funded grants. Dr. Doros authored and co-authored many peer-reviewed publications of original and innovative research which has had a major impact on the field. On the majority of publications, Dr. Doros is the lead statistician author. He demonstrated continuing record of multidisciplinary research that has had a major impact on the rapidly changing field. His publications on clinical trials; most proposing the design, analysis and new methodologies or of significant contributions to this field.

Dr. Doros is a very active and effective teacher and mentor in the department of Biostatistics. His teaching philosophy is to pursue an active approach to learning and to engage students to think critically. He taught core and elective courses for Master and PhD-level courses. The excellent course evaluations he received attests to his ability in engaging students in active learning. Dr. Doros has been awarded the excellence in teaching three times in three years.

On a national level, Dr. Doros has served as an Associate Editor for the BioMed Central’s journal Trials and as a reviewer for a number of academic journals. He served as a member of the merit review subcommittee for Epidemiology of the Department of Veteran Affairs and a member NHLBI-Ancillary Studies in Clinical Trials between 2012 and 2014. He has served as a statistical expert on a number of Independent Data Monitoring Committee(IDMC) for clinical trials and clinical programs. He served or seves as a senior consultant on multicenter trials and/or programs for the following organizations Pfizer, Takeda, Avanir, Sarepta and Children's Hospital.

Other Positions

  • Member, BU-BMC Cancer Center - Boston University
  • - Boston Medical Center

Education

  • Yale University, PhD Field of Study: Statistics
  • Yale University, MA Field of Study: Statistics
  • University of Bucharest, MS Field of Study: Statistics
  • University of Bucharest, BS Field of Study: Mathematics

Websites

Classes Taught

  • SPHBS849
  • SPHBS853
  • SPHBS980

Publications

  • Published on 4/21/2023

    Rabbat MG, Lakshmanan S, Benjamin MM, Doros G, Kinninger A, Budoff MJ, Bhatt DL. Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT. Eur Heart J Cardiovasc Imaging. 2023 Apr 21. PMID: 37082990.

     Read At: PubMed
  • Published on 4/3/2023

    Cannon CP, Kim JM, Lee JJ, Sutherland J, Bachireddy R, Valentine CM, Hearne S, Trebnick A, Jaffer S, Datta S, Semmel E, Thorpe F, Doros G, Cavender MA, Reynolds MR. Patients and Their Physician's Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an Anticoagulant. JAMA Netw Open. 2023 Apr 03; 6(4):e239638. PMID: 37093601.

     Read At: PubMed
  • Published on 4/1/2023

    Sandner S, Misfeld M, Caliskan E, Böning A, Aramendi J, Salzberg SP, Choi YH, Perrault LP, Tekin I, Cuerpo GP, Lopez-Menendez J, Weltert LP, Böhm J, Krane M, González-Santos JM, Tellez JC, Holubec T, Ferrari E, Doros G, Vitarello CJ, Emmert MY. Clinical outcomes and quality of life after contemporary isolated coronary bypass grafting: a prospective cohort study. Int J Surg. 2023 Apr 01; 109(4):707-715. PMID: 36912566.

     Read At: PubMed
  • Published on 1/17/2023

    Cavanagh CE, Rosman L, Chui P, Minges K, Desai NR, Goodlin S, Fedson S, Spertus JA, Gluckman TJ, Song Y, Zheng L, Turchin A, Doros G, Lee JJ, Burg MM. Advance Care Planning and End-of-Life Education in Heart Failure: Insights From the NCDR PINNACLE Registry. Circ Cardiovasc Qual Outcomes. 2023 Jan; 16(1):e008989. PMID: 36649391.

     Read At: PubMed
  • Published on 9/27/2022

    Krishnan P, Farhan S, Schneider P, Kamran H, Iida O, Brodmann M, Micari A, Sachar R, Urasawa K, Scheinert D, Ando K, Tarricone A, Doros G, Tepe G, Yokoi H, Laird J, Zeller T. Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention. J Am Coll Cardiol. 2022 Sep 27; 80(13):1241-1250. PMID: 36137674.

     Read At: PubMed
  • Published on 9/26/2022

    Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes. JACC Cardiovasc Interv. 2022 Sep 26; 15(18):1852-1860. PMID: 36137689.

     Read At: PubMed
  • Published on 9/10/2022

    Kuku KO, Garcia-Garcia HM, Doros G, Mintz GS, Ali ZA, Skinner WH, Artis AK, Ten Cate T, Powers E, Wong SC, Wykrzykowska J, Dube S, Kazziha S, van der Ent M, Shah P, Sum S, Torguson R, Di Mario C, Waksman R. Predicting future left anterior descending artery events from non-culprit lesions: insights from the Lipid-Rich Plaque study. Eur Heart J Cardiovasc Imaging. 2022 Sep 10; 23(10):1365-1372. PMID: 34410335.

     Read At: PubMed
  • Published on 8/18/2022

    Havasi A, Heybeli C, Leung N, Angel-Korman A, Sanchorawala V, Cohen O, Wechalekar A, Bridoux F, Jaffer I, Gutgarts V, Hassoun H, Levinson M, Rosenbaum C, Milani P, Palladini G, Merlini G, Hegenbart U, Schönland S, Veelken K, Pogrebinsky A, Doros G, Landau H. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group. Blood Cancer J. 2022 Aug 18; 12(8):119. PMID: 35982035.

     Read At: PubMed
  • Published on 7/21/2022

    Demola P, Di Mario C, Torguson R, Ten Cate T, Bambagioni G, Ali Z, Skinner W, Artis A, Zhang C, Garcia-Garcia HM, Doros G, Mintz GS, Waksman R. Greater plaque burden and cholesterol content may explain an increased incidence of non-culprit events in diabetic patients: a Lipid-Rich Plaque substudy. Eur Heart J Cardiovasc Imaging. 2022 Jul 21; 23(8):1098-1107. PMID: 34568945.

     Read At: PubMed
  • Published on 7/4/2022

    Staron A, Zheng L, Doros G, Sanchorawala V. Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans. Blood Cancer J. 2022 07 04; 12(7):100. PMID: 35787622.

     Read At: PubMed

View 327 more publications:View Full Profile at BUMC

News & In the Media

View all profiles